The Beneficial Effect of Combined GH/GnRHa Therapy in Increasing Adult Height Outcome in Children with ISS

Liora Lazar*, Sigal Levy, Tal Oron, Joseph Meyerovitch, Liat De Vries, Shlomit Shalitin, Ariel Tenenbaum, Moshe Phillip, Yael Lebenthal

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Context Management of GH-treated children with idiopathic short stature (ISS) with early puberty and adolescents in midpuberty at initiation of treatment is challenging. Objective To assess the effect of combined GH/GnRHa therapy during puberty on achieved adult height (AHt) in these children with ISS and to determine whether outcome depended on sex and pubertal status at initiation of GH therapy. Design Retrospective, single-center observational study from 2003-2018. Setting Tertiary endocrine center. Patients One hundred ninety-two GH-treated children with ISS; 58 of 192 were treated by GH/GnRHa during puberty; 31 of 58 were prepubertal (19 girls) and 27 of 58 pubertal (19 girls) at initiation of GH. Main Outcome Measures AHt, gain-in-height standard deviation score (SDS), AHt vs predicted adult height (PAHt), AHt vs target height (THt). Results Most boys and girls attained AHt SDS within the normal range (-0.73 ± 0.60 and -0.85 ± 0.65, respectively). Treatment modality, pubertal status, and sex were tested for their joint effect on growth outcome measures. Combined GH/GnRHa therapy increased AHt vs PAHt (P < 0.001) and AHt vs THt (P = 0.035). Prepubertal status at onset of GH treatment increased AHt (P = 0.049), gain-in-height SDS (P < 0.001), AHt vs PAHt (P < 0.001), and AHt vs THt (P = 0.042). Female sex increased AHt vs PAHt (P < 0.001). Conclusions Our study demonstrated a beneficial effect of combined GH/GnRHa therapy in increasing AHt outcome in children with ISS with early/normal puberty and in adolescents naïve to GH treatment who are in midpuberty at initiation of therapy. This effect was more pronounced in the prepubertal group and in girls. Prospective randomized controlled trials are needed to assess whether GnRHa can increase AHt in GH-treated children with ISS.

Original languageEnglish
Pages (from-to)3287-3295
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Issue number8
StatePublished - 19 Jun 2019


FundersFunder number
Novo Nordisk


    Dive into the research topics of 'The Beneficial Effect of Combined GH/GnRHa Therapy in Increasing Adult Height Outcome in Children with ISS'. Together they form a unique fingerprint.

    Cite this